McKesson Corporation $MCK Shares Purchased by Ferguson Wellman Capital Management Inc.

Ferguson Wellman Capital Management Inc. boosted its stake in McKesson Corporation (NYSE:MCK) by 3.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 28,236 shares of the company’s stock after buying an additional 935 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in McKesson were worth $21,335,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in MCK. University of Texas Texas AM Investment Management Co. purchased a new position in McKesson during the 4th quarter valued at about $25,000. Swiss RE Ltd. acquired a new stake in shares of McKesson in the 4th quarter valued at $26,000. Delos Wealth Advisors LLC purchased a new stake in shares of McKesson during the 2nd quarter worth $27,000. State of Wyoming acquired a new position in shares of McKesson during the second quarter worth $29,000. Finally, Kingdom Financial Group LLC. purchased a new position in McKesson in the fourth quarter valued at $33,000. 85.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at McKesson

In other news, Director Bradley E. Lerman sold 301 shares of McKesson stock in a transaction on Monday, August 10th. The shares were sold at an average price of $892.33, for a total value of $268,591.33. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Brian S. Tyler sold 8,463 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the completion of the sale, the chief executive officer owned 5,919 shares of the company’s stock, valued at approximately $4,697,081.64. This trade represents a 58.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 23,111 shares of company stock valued at $18,011,274. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on MCK shares. Evercore reaffirmed an “outperform” rating on shares of McKesson in a report on Thursday, August 6th. UBS Group boosted their target price on McKesson from $1,050.00 to $1,080.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. TD Cowen upped their price target on McKesson from $989.00 to $1,006.00 and gave the company a “buy” rating in a report on Thursday, August 6th. Royal Bank Of Canada began coverage on shares of McKesson in a research note on Wednesday, August 19th. They issued a “sector perform” rating and a $845.00 price target on the stock. Finally, Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $973.44.

McKesson Stock Performance

MCK opened at $895.59 on Friday. The business’s 50-day simple moving average is $833.31 and its 200-day simple moving average is $844.13. McKesson Corporation has a one year low of $679.65 and a one year high of $999.00. The stock has a market capitalization of $104.42 billion, a P/E ratio of 23.97, a price-to-earnings-growth ratio of 1.75 and a beta of 0.30.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.56 by $0.37. The firm had revenue of $105.38 billion during the quarter, compared to analysts’ expectations of $103.88 billion. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%.The business’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the firm earned $8.26 EPS. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. On average, equities research analysts forecast that McKesson Corporation will post 44.65 EPS for the current fiscal year.

McKesson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Tuesday, September 1st will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. This is a boost from McKesson’s previous quarterly dividend of $0.82. The ex-dividend date is Tuesday, September 1st. McKesson’s payout ratio is 8.78%.

Trending Headlines about McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: Expansion into precision medicine: McKesson agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion. Precision Medicine provides clinical research, laboratory testing and commercialization services for biotechnology and pharmaceutical companies, giving McKesson greater exposure to oncology, personalized medicine and specialty care. McKesson Doubles Down on Healthcare Growth With Precision Medicine Acquisition
• Positive Sentiment: Higher-growth service mix: The acquisition is expected to strengthen McKesson’s clinical research and commercialization capabilities and deepen relationships with biopharmaceutical companies and oncology practices. Investors may view the transaction as a way to reduce reliance on lower-margin pharmaceutical distribution and participate in growth tied to new drug development. What Does McKesson Gain From Its Push Into Oncology And Clinical Research?
• Neutral Sentiment: Portfolio repositioning amid workforce changes: Coverage noted layoffs at Rx Savings while McKesson plans the Precision Medicine acquisition. The combination highlights an ongoing reallocation of resources, although the near-term effect on earnings and integration costs remains uncertain. Amid Layoffs, McKesson Plans Acquisition
• Negative Sentiment: Cybersecurity incident disclosed: McKesson reported discovering a cybersecurity incident on August 25 after the ShinyHunters group claimed it had stolen patient data. The company’s investigation and any resulting regulatory, remediation, privacy or reputational costs could weigh on sentiment, although the ultimate scope and financial impact were not yet clear. McKesson Discloses Breach After ShinyHunters Claims Patient Data Theft

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.